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Abstract 
The development of a translational research path has traditionally been a haphazard approach, filtering technologies so 
that the ‘best of breed’ may ultimately succeed. The conversion ratio of brilliant ideas to useful devices remains suboptimal, 
as many ‘fail to progress’. The reality of developing biotechnology transfer and Knowledge Transfer (KT) generally, is that 
the ability of multidisciplinary teams (MDT) to assimilate and then act upon information is becoming the rate limiting step 
for the building of complex projects. The model proposed here considers both the biological aspects of Life Sciences (LS) and 
the establishment of Technology Readiness for its implementation. 
By offering a sustainable generic structure for the assimilation and transfer of technologies, at a rate supported by 
the individual teams, the potential is for a standalone system able to accommodate clinical research and governance 
needs. The construction of a "signature", which reflects the current state of development, and through the rate progress of 
translation,  and  development  of  these  technologies,  potentially  allows  us  to  draw  comparisons  across  different 
multidisciplinary environments, so as to ensure that adequate resources are allocated to assure their interoperability 
within agreed timescales. 
A case example applying this process to  the  development of a ‘force sensing’ lightweight  hand rim for  manual 
wheelchairs allowed for the kinematic data to be compared with Electromyographic (EMG muscle patterning) data. This 
demonstrates that this strategic approach can be operationalized. By mapping the EMG signals from the basic science 
experiments through to clinical evaluation, the groundwork for assuring rapid integration of approaches for the afferent 
arm of novel ‘autosensing’ FES technologies. This integrates with work practices across disciplines, so as to create a 
potential ‘template’ for integration into Standard Operating Procedures (SOPs). These accommodate established ‘Good 
Laboratory Practice’ (GLP) and also can meet the requirements for governance of the translational research framework. 
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Introduction 
‘Reinventing the wheel’ is a relatively simple task 
for  modern  engineering.  Certain  obvious 
characteristics are evident and have stood the test of 
time, but as sensing technologies develop, so does our 
potential  to  harness  the  Human  Machine  Interface 
(HMI).  By  near-real-time  analysis  of  data  that  it 
generates,  we  can  create  novel  opportunities  for 
technologies  to  play  a  key  role  by  providing  insight 
into how we may optimise our environment, through 
adaptation  to  our  human  performance  and  its 
limitations.  Spinal  cord  injured  manual  wheelchair 
users  suffer  significant  shoulder  problems(1)  since 
they are over dependent on their arms for propulsion. 
Instrumentation of their activity is therefore aimed at 
developing protective strategies. 
For  the  purpose  of  establishing  a  rapid 
prototyping  and  testing  system  for  mapping  EMG 
patterns to kinetic activity, the Translational Research 
approach  was  applied  to  ensure  rapid  translation 
within a short time frame for optimal development of 
approaches for ‘afferent limb’ activity modelling in the 
upper  limb.  A  kinematic  sensing  system  was  thus 
developed  for  manual  wheelchair  users  (MWUs) 
which  is  both  lightweight  and  can  provide  the  data 
that can be multiplexed with other ‘streams’, including 
16  channel  EMG,  to  ensure  interoperability  with 
modular assistive technologies. It is possible to initiate 
a  technology  transfer  pipeline  with  Knowledge 
Transfer (KT) from multidisciplinary academic teams, 
through  development  teams  to  potential  industrial 2 
 
partners, in anticipation of future productisation and 
commercialisation.  
This  traditional  engineering  process  of  "design 
and build” has been modified to "co-design" and "co-
build"  in  order  to  accommodate  multidiscipliniarity, 
methods of validation and testing. This demonstrates 
the potential to adopt open and flexible models for the 
development  of  large  complex  systems  as  a  way  of 
streamlining  the  knowledge  transfer  from  academic 
research to development projects. 
The  widespread  adoption  of  the  Technology 
Readiness  Level  (TRL)  scale  (Figure  1)  demystifies 
technological  maturity  and  helps  to  operationalize 
roadmaps that strategically direct research themes.   
This  reflects  the  traditional  technology  transfer 
"cascade",  but  identifies  nine  clear  (discrete)  stages. 
This only reveals part of the story. With development 
of increasingly complex systems, multiple systems and 
subsystems  may  interact,  so  interoperability  is  vital. 
For this reason, it is necessary to consider the system 
readiness,  invoking  different  evaluation  approaches, 
which are equally valid, and yet often refer to different 
parameters.  It  is  therefore  not  possible  to  compare 
these  directly.  Instead  it  is  practical  to  represent 
progress  in  terms  of  a  "signature",  reflecting  the 
relative progress of the different subsystems.  
Ultimately  we  need  to  ensure  adequate 
interoperability  for  entire  systems  to  be  deployed, 
especially  in  a  clinical  environment  where  risk  of 
adverse events necessitates clear governance and risk 
mitigation. 
 
Governance 
It is essential that we are able to integrate clinical, 
research  and  governance  information.  This  must 
comply with the  necessary standards  of information 
required  ‘downstream’  for  appropriate  Foods  and 
Drugs Administration (FDA) and European Medicines 
Agency (EMA) approvals for the North American and 
European markets respectively. 
By  developing  the  appropriate  technology 
transfer environment, it is possible to accelerate the 
process, ensuring that for example; Good Laboratory 
Practice  (GLP)  is  managed  within  the  University 
environment,  and  then  translated  according  to  the 
criteria  for  Good  Clinical  Practice  (GCP),  to  ensure 
compliance  for  clinical  trials.  Following  successful 
completion of these validation studies, it is necessary 
to  consider  aspects  of  Good  Manufacturing  Practice 
(GMP) and to recognise the special importance in the 
medical arena of a ‘safe mode to failure’. In cases where 
failure is anticipated, it is necessary to extend this to 
consider  the  appropriate  surveillance,  which  is 
metered in proportion to the risk. 
By adopting a translational research path where 
the provenance of technologies can be demonstrated 
in terms of an empirical methodology, each ‘column’ 
has as its foundation the data which is analysed by the 
investigators  at  each  stage.  This  is  synthesised  and 
evaluated so as to create clearer understanding that 
allows the team to progress to the next stage. 
Figure 1 Mapping the Technology Readiness Level (TRL) on to the Stages of technical research and development 3 
 
Broadly speaking, the first three stages (TRL1-3) 
occur in the University environment. They lead from 
initial idea to design and testing for the initial ‘Proof of 
Concept’  (POC)  development.  This  creates  many 
potential  opportunities  that  can  be  taken  forward, 
ultimately with a view to potential productisation. The 
next three technology readiness levels (TRL4-6) take 
the initial proof of concept; build demonstrations, for 
testing and validation using appropriate scenarios and 
environments.  In  the  case  of  biologically  interactive 
technologies  (Clinical  Trials  of  Investigational 
Medicinal  Products  -  CTIMP  and  Advanced 
Therapeutic  Medicinal  Products  -  ATMP),  the  ‘pipe’ 
has clearly defined animal models followed by Phase I 
(first in humans), Phase II (safety and efficiency) and 
Phase  III  (clinical  effectiveness)  trials.  A  similar 
approach for implantable devices is inevitable in the 
future, even if presently not regulated for. 
This process will therefore go from the theoretical 
methodological  preparation  stage  of  protocol 
generation  through  to  a  practical  application 
evaluation stage, such as the clinical study or formal 
testing, as is the case with software development. 
Transitioning from TRL6  to 7 ensures that  new 
system components are integratable into a ‘real-world’ 
working environment, and again through TRL8, there 
is likely to be a formal evaluation stage. This may be 
through  Health  Technology  Assessment  which  is 
usually  managed  within  each  jurisdiction,  or  some 
type  of  later  Phase  IV  (implementation  oriented) 
clinical  trial,  which  will  extend  beyond  the  initial 
indications of the formal validation in the case of the 
Clinical  Trials  of  Investigational  Medicinal  Products 
(CTIMP). 
Ultimately  the  real  ‘test’  for  any  system  is  its 
potential to impact upon the market, and thus success 
is  indicated  by  evaluation  of its  impact  at  the  TRL9 
stage.  Identifying design flaws at this stage is clearly 
‘too late’ for correction. 
Cross-cutting this technology assessment tool, is 
the realistic appraisal as to which biological scales are 
relevant.  At  the  beginning  of  the  spectrum  (10-8m), 
aspects  of  the  technology  that  impact  at  the  genetic 
level will be communicated biologically through gene 
expression  to  the  proteomic  level,  which  drives  the 
metabolome and hence influences the metabolic level. 
These physiological systems work on sub cellular and 
cellular systems, which clearly impact upon the ability 
of  tissues  to  perform  their  functions,  to  withstand 
stresses  which  challenge  homoeostatic  mechanisms. 
As tissues are specialised within organs, so the organs 
combine  to  represent  the  systems  such  as  the 
peripheral nervous system or musculoskeletal system. 
There is of course a significant relationship between 
these subsystems of the body, such as the coordinated 
actions of the neuromusculoskeletal axis, to affect the 
wishes of an individual. 
Extending  beyond  this  scale,  is  the  relationship 
that  individual  has  with  their  local,  family  group  or 
individuals  who  may  be  clustered  with  respect  to 
certain  clinical  conditions.  Either  way,  these 
individuals  and  groups  contribute  to  their  relevant 
community,  whose  expertise  in  living  with  clinical 
conditions and feedback, drive research teams. This is 
broadly termed ‘public and patient involvement’ (PPI). 
This  ultimately  has  an  impact  at  the  political  level, 
where there is the need to apply the strategic thinking 
necessary  to  address  epidemiological  challenges. 
Whilst this Life Science (LS) scale effectively considers 
research  issues  in  isolation,  for  the  purposes  of 
biotechnology transfer, this provides a simple matrix 
that relates one level to another and one step to the 
next.  This  process  may  require  demonstration  of 
correlation, with experimental (empirical) data, or it 
may represent a transition across levels, which may be 
of scientific or administrative value. 
 
Validation & Verification 
Development of "soft" and "hard" gates is relevant 
to how we are building different translational research 
pipelines.  These  may  alternately  represent  protocol 
development  and  testing,  acting  as  a  coordinating 
force to ensure that subsystems are brought "online" 
at  an  appropriate  rate  for  their  integration  and 
ultimate  interoperability.  These  “soft”  gates  warrant 
internal  peer  review  only,  compared  with  external 
peer  review  at  the  “hard”  gates  such  as  requesting 
ethical opinion or sponsor approvals. 
Tempered with these approaches, is the need to 
build  in  risk  assessment  at  various  stages  in 
accordance  with  the  criteria  to  meet  necessary 
governance  regulations.  Progressing  to  the  stage 
where  modular  systems  design  and  development  is 
normal, simple systems become complex, so too, the 
complex  systems  on  which  these  depend,  become 
complicated,  as  they  rely  on  interactions  with  other 
components. 
Indeed  there  are  some  situations  which  are  so 
complicated  that  the  only  rational  approach  to  this 
chaotic environment, such as the global ‘race’ to meet 
the next ‘grand challenge’, is to run parallel paths of 
development - to ultimately support the best of breed, 
which ultimately appears as a clear leader. 
This is the approach adopted by funding agencies, 
i.e.  no  single  group  can  work  in  isolated  academic 
splendour.  It  is  therefore  the  ability  to  convene 
multidisciplinary teams with the minimum resource at 
short  notice,  and  for  them  to  be  able  to  work  in  a 
shared  real  or  Virtual  Research  Environment  (VRE) 4 
 
(2)(see  figure  2  below),  which  will  ultimately  gives 
them the competitive edge.  
 
 
Figure 2 Virtual research integration and 
collaboration environment 
 
 
This  represents  a  degree  of  optimisation  of  the 
‘systems’ approach, with gating procedures to ensure 
appropriate regulation for  the protection of subjects 
(such as the necessary institutional review board – IRB 
reviews)  and  also  to  ensure  that  pre-productised 
devices are ready for progressing to their next stage of 
development.  
Ultimately the value to institutions is the ability to 
discretely categorise stages of progress to either offer 
support or to ‘cull’ research and development efforts 
that are clearly not going to be productive. Precautions 
should be taken to avoid the ‘culling’ process too early, 
since  history  clearly  demonstrates  that  the  ultimate 
true value of potential new technologies e.g. the laser, 
may take at least two decades to be realised, and often 
for previously unanticipated applications. 
This  ensures  that  the  groups  and  teams  are 
assured that their intellectual property is adequately 
protected,  supporting  the  interests  sponsors  and 
institutions. 
 
Ensuring Technical Knowledge Transfer  
The  aim  of  the  ‘PowerWheel’  project  was  to 
ensure a validated sensing wheel that could be ‘rolled 
out’ prior to the Paralympics in London in 2012. This 
is a clear deadline which focuses the world’s attention 
and offers an opportunity to find a commercial partner 
for  the  next  phase  of  development.  Success  of  the 
validation  process  depended  on  the  transfer  of 
expertise from the basic science laboratory to the test 
environments. This was exemplified by analysis of the 
EMG data that was synchronized with the kinematic 
data.  
This  technique  was  validated  in  a  wheelchair 
propulsion  laboratory  (TRL2)  in  Canada,  and  then 
applied in the study of a population of 30 healthy able 
bodied  individuals  (UCL  PAMELA  laboratory,  UK) 
representing  validation  in  a  relevant  environment 
(TRL5).  Finally  the  system  was  evaluated  in  an 
operational  environment  (TRL7)  at  the  Stanmore 
Clinical  Research  Facility,  involving  7  spinal  cord 
injured patients from the London Spinal Cord Injury 
Centre. 
 
Wavelet analysis of the EMG signal 
EMG data were normalized to percentage of cycle 
time  and  synchronized  with  kinetic  data.  All  signal 
processing  was  performed  using  custom  programs, 
written using Mathematica (version 6.0, Wolfram Inc., 
Champaign, IL, USA). The EMG signals were resolved 
into intensities in time-frequency space using wavelet 
techniques(3). The intensity is a close approximation 
to the  power  of the  signal  contained  within  a  given 
frequency  band,  and  the  intensity  spectrum  is 
equivalent to the power spectrum from the signals. A 
filter bank of 10 non-linearly scaled wavelets was used, 
index by k, with center frequency, fc, ranging from 7 
Hz (wavelet 0) to 350 Hz (wavelet 9). The first wavelet 
of EMG covered a frequency band of 0-10 Hz, which is 
typically associated with movement artifacts.  
The  effects  of  movement  due  to  dynamic 
contractions  were  reduced  by  removing  the  first 
wavelet from the spectra. Total intensity was given by 
summing  the  intensities  over  the  selected  wavelets 
(10-350 Hz, k = 1-9). Total intensity is a measure of 
the  time-varying  power  within  the  signal  and  is 
equivalent  to  twice  the  square  of  the  root-mean-
square (2rms2).  This technique was uniformly applied 
across the three studies, at stages TRL2, 5 and 7. 
EMG activities 
EMG  signals  represent  the  activity  of  an  organ 
(muscle) and collectively the patterning represents an 
anatomical  system,  in  this  case  the  shoulder  joint 
musculature. Wheelchair propulsion involves 2 phases, 
the  push  and  the  recovery  phase  (4;5).  Anterior 
deltoid,  pectoralis  major,  biceps,  and  triceps  have 
primary activity during the push phase for the forward 
push. The general pattern of push phase muscles was 
characterized  by  the  onset  of  activity  in  the  late 
recovery  phase  during  the  arm  return  and  push 
preparation  phases.  The  EMG  intensity  of  these 
muscles  was  higher  in  sprint  than  in  straight  push, 
which indicates that fast speed wheelchair propulsion 
places  higher  load  on  these  shoulder  muscles  and 
hence requires higher muscle activation levels. Similar 
patterns of activity were seen at all three validation 
stages. 
After  the  follow-through  of  the  push  phase,  the 
shoulder motions reversed direction in  the  recovery 
phase.    The  recovery  muscles,  middle  deltoid, 
supraspinatus,  latissimus  dorsi,  and  subscapularis, 
contracted  eccentrically  to  restrain  shoulder  flexion 
and then contracted concentrically to return the arm 5 
 
to its starting position.  The EMG intensities of these 
muscles were significantly higher for sprint than for 
straight  push,  which  may  be  associated  with  rapid 
movement  in  the  recovery  phase.  Participants 
executed  the  propulsion  cycle  faster  to  maintain 
increased speed. 
Compared  to  forward  push,  the  tested  muscles 
displayed  different  patterns  in  backward  push.  The 
push  muscles  were  active  during  the  mid-push  and 
mid-recovery  phase,  whereas  the  recovery  muscles 
were active during  the late-recovery and early push 
phases. The EMG intensity of push muscles was lower 
in  backward  push  than  in  forward  push,  while  the 
recovery  muscles  showed  a  higher  EMG  activity  in 
backward  push  than  in  forward  push.  It  has  been 
reported that long term use of the manual wheelchair 
leads  to  muscle  imbalance,  overdevelopment, 
strengthening and shortening of the anterior deltoid 
and pectoralis with weakening and lengthening of the 
opposing muscle groups (6-10). Backward push would 
therefore  be  a  good  exercise  for  manual  wheelchair 
users to strengthen posterior musculature.  
 
Conclusions  
At  different  stages  of  the  translational  research 
pipe,  demonstration  of  the  consistency  of  EMG 
patterning  across  the  validation  steps,  coordinated 
with  consistent  kinematic  data  collection,  suggests 
that  the  wheel  could  transition  to  its  next  step  for 
development, with confidence that it effectively adds 
value.  This  demonstration  supported  real 
collaboration  across  multidisciplinary  teams 
representing  Neurophysiology,  Engineering, 
Rehabilitation Medicine and Orthopaedics. It covered 
initial University research and development (TRL1-3) 
plus  engineering  and  evaluation  in  a  healthy 
population,  (TRL4-6)  development  stages.  Rapid 
transition through to a nationally supported (UK NIHR 
i4i FDP1) clinical trial of spinal cord injured patients 
(TRL7), demonstrates the potential for this approach 
to  develop  a  truly  competitive  edge  in  a  global 
research and development environment. 
As  Darwin  stated(11);  "In  the  struggle  for 
survival, the fittest win out at the expense of their 
rivals because they succeed in adapting themselves 
best to their environment." The  reality  is  that  major 
scientific endeavour is now a global exercise. It is the 
ability  to  rapidly  configure  groups  to  focus  on 
challenges  and  complete  stages  effectively  that  will 
ensure their long term survival. VREs are likely to play 
a central role in this in the future. 
This  means  that  the  teams  need  to  respect  the 
logical transition and the consistent  extrapolation  of 
an  argument  from  one  step  to  the  next.  It  is  the 
provenance  of  data  which  ultimately  secures  the 
foundation  of  clinical  intervention  in  a  sound  basic 
science  evidence  base.  We  must  all  adapt  our 
technologies  to  ensure  rapid,  reliable  and  robust 
transfer through the progressive levels of readiness to 
the  point  that  they  can  be  implemented  safely  and 
securely for the benefit of all. 
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